The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter

被引：0
|
作者：
Leon, Leticia G. [1 ,2 ]
Funel, Niccola [1 ]
Peters, Godefridus J. [3 ]
Avan, Amir [4 ,5 ]
Vistoli, Fabio [6 ]
Boggi, Ugo [6 ]
Giovannetti, Elisa [1 ,3 ]
机构：
[1] Univ Pisa, Canc Pharmacol Lab, AIRC Start UP Unit, I-56124 Pisa, Italy
[2] Univ La Laguna, Ctr Biomed Res Canary Isl, Inst Tecnol Biomed, E-38207 San Cristobal la Laguna, Spain
[3] VU Univ Med Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[4] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Sch Med, Mashhad, Iran
[5] Mashhad Univ Med Sci, Canc Res Ctr, Sch Med, Mashhad, Iran
[6] Univ Pisa, Div Gen & Transplant Surg, I-56124 Pisa, Italy
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 10期
关键词：
PANCREATIC-CANCER; ANTITUMOR-ACTIVITY;
D O I：
10.1158/1078-0432.CCR-16-0259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2594 / 2594
页数：1
相关论文
共 50 条
  • [1] The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response
    Vena, Francesca
    Hartley, John A.
    Hochhauser, Daniel
    CLINICAL CANCER RESEARCH, 2016, 22 (10) : 2595 - 2595
  • [2] The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response (vol 22, pg 2595, 2016)
    不详
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5619 - 5619
  • [3] Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor
    Nuggehally R. Srinivas
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 373 - 382
  • [4] Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor
    Srinivas, Nuggehally R.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (04) : 373 - 382
  • [5] The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
    Vena, Francesca
    Li Causi, Eleonora
    Rodriguez-Justo, Manuel
    Goodstal, Samantha
    Hagemann, Thorsten
    Hartley, John A.
    Hochhauser, Daniel
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5563 - 5577
  • [6] PIMASERTIB HYDROCHLORIDE MEK1/2 inhibitor Treatment of malignant melanoma
    Gambardella, V.
    Sforza, V.
    Troiani, T.
    Martini, G.
    Napolitano, S.
    Cardone, C.
    Ferrara, M. L.
    Nappi, A.
    Manzo, A.
    Capasso, A.
    Morgillo, F.
    Rosello, S.
    Cervantes, A.
    Ciardiello, F.
    Martinelli, E.
    DRUGS OF THE FUTURE, 2016, 41 (07) : 405 - 410
  • [7] Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors
    Scheible, Holger
    Kraetzer, Friedrich
    Marx, Andreas
    Johne, Andreas
    Wimmer, Elmar
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (02) : 174 - 182
  • [8] Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
    Ravandi, F.
    Pigneux, A.
    DeAngelo, D. J.
    Raffoux, E.
    Delaunay, J.
    Thomas, X.
    Kadia, T.
    Kantarjian, H.
    Scheuenpflug, J.
    Zhao, C.
    Guo, W.
    Smith, B. D.
    BLOOD CANCER JOURNAL, 2015, 5 : e375 - e375
  • [9] Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
    F Ravandi
    A Pigneux
    D J DeAngelo
    E Raffoux
    J Delaunay
    X Thomas
    T Kadia
    H Kantarjian
    J Scheuenpflug
    C Zhao
    W Guo
    B D Smith
    Blood Cancer Journal, 2015, 5 : e375 - e375
  • [10] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
    Delord, Jean-Pierre
    Italiano, Antoine
    Awada, Ahmad
    Aftimos, Philippe
    Houede, Nadine
    Lebbe, Celeste
    Pages, Celine
    Lesimple, Thierry
    Dinulescu, Monica
    Schellens, Jan H. M.
    Leijen, Suzanne
    Rottey, Sylvie
    Kruse, Vibeke
    Kefford, Richard
    Faivre, Sandrine
    Gomez-Roca, Carlos
    Scheuler, Armin
    Massimini, Giorgio
    Raymond, Eric
    TARGETED ONCOLOGY, 2021, 16 (01) : 37 - 46
12345